Treatment
SGLT2 inhibitor clinical trials
We’re tracking 44 recruiting studies that include SGLT2 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT05852704RecruitingPhase 3
Dapagliflozin to prevent irregular heart rhythm after bypass surgery
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
BrnoAges 18 years+ - NCT06055452RecruitingPhase 4
SGLT2 Inhibitors for Pre-Heart Failure with Hypertension
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06155604RecruitingPhase 2
SGLT2 inhibitor for lupus nephritis with kidney disease
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
Hong KongAges 18 years+ - NCT06435858RecruitingPhase 2
SGLT2 inhibitor for calcium and magnesium in ADPKD
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help control calcium and magnesium levels in people with a genetic kidney disease called ADPKD. The goal is to see if it improves kidney health over a short period.
Zurich, Canton of ZurichAges 18–75 - NCT06600178RecruitingPhase 1
Heart medication for women with chest pain and small vessel disease
This trial tests a diabetes medication called SGLT2 inhibitors to see if it can improve blood flow to the heart and reduce chest pain in women who have small vessel heart disease (microvascular dysfunction) but not blocked large arteries. Participants will take the medication and be monitored for symptom relief and heart function improvements.
Charlottesville, VirginiaAges 18 years+ - NCT06609356RecruitingEarly Phase 1
Reducing high insulin levels in type 1 diabetes
This study tests if adding a non-insulin medication can lower the amount of insulin needed while improving heart and metabolic health in people with type 1 diabetes. It may also help understand how this approach works in people with a genetic form of diabetes (GCK-MODY).
Nashville, TennesseeAges 18–60 - NCT06929169RecruitingPhase 2
SGLT2 inhibitor heart health study in dialysis patients
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
Buenos Aires, Buenos AiresAges 18–70 - NCT06932081Recruiting
Study of SGLT2i in adults with congenital heart disease
This trial is a registry that follows adults with congenital heart disease who have started taking an SGLT2 inhibitor medication. The goal is to learn how well this treatment works for this group of patients.
Baltimore, MarylandAges 18 years+ - NCT07174687RecruitingPhase 2
SGLT2 inhibitor drug for geographic atrophy in dry AMD
This trial tests whether an SGLT2 inhibitor (a diabetes drug) can help slow geographic atrophy, a type of advanced dry age-related macular degeneration. It might be an option if you have dry AMD with specific types of retinal damage and haven't had other treatments.
St Louis, MissouriAges 50 years+ - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07214818RecruitingPhase 2/Phase 3
SGLT2 Inhibitors for Adult Primary Nephrotic Syndrome
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07237451Recruiting
Heart and kidney study of SGLT2 inhibitors
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
IașiAges 18 years+ - NCT07309094Recruiting
Effects of a diabetes drug on fat tissue in kidney disease
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
Valencia, ValenciaAges 18–90 - NCT07491042Recruiting
A study of SGLT2 inhibitors for people on peritoneal dialysis
This study tests whether a type of diabetes medicine called SGLT2 inhibitors (which help lower blood sugar and protect the kidneys) can benefit people who are on chronic peritoneal dialysis. You may be able to join if you are 13 or older, have some urine output, and do not have certain other health issues.
NizwaAges 13 years+ - NCT07572032RecruitingPhase 4
Heart failure recovery after valve or coronary surgery
This study tests when to start two heart-protective medications (ARNI and SGLT2 inhibitors) after you've had surgery to fix a valve problem or blocked heart arteries. Researchers want to see if waiting a bit before starting these drugs helps your heart recover better.
Daegu, DaeguAges 18 years+ - NCT07614230RecruitingPhase 4
SGLT2 drugs and heart artery health in diabetes
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
Beijing, Beijing MunicipalityAges 18–78 - NCT06972732RecruitingPhase 4
Comparing three diabetes drugs for type 2 diabetes
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
Seoul, Seocho DistrictAges 19 years+ - NCT06443645Recruiting
Protecting the heart during breast cancer treatment
This trial tests whether a diabetes medicine (SGLT2 inhibitor) can prevent heart damage caused by a common chemotherapy drug (anthracycline) in people with early-stage breast cancer. If you are newly diagnosed and about to start chemotherapy or have surgery, this study may be for you.
StrasbourgAges 18 years+ - NCT05305911RecruitingPhase 2
SGLT2 drug after first heart attack to reduce heart damage
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
Minneapolis, MinnesotaAges 18–75 - NCT05715814RecruitingPhase 3
Test diabetes-pill type medicine on kidney dialysis safety
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
Toronto, OntarioAges 18 years+
Common questions
- Are there clinical trials studying SGLT2 inhibitor?
- Yes. Clin2 currently lists 44 recruiting studies that include SGLT2 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SGLT2 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SGLT2 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SGLT2 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.